Figure 3.
Schema for Phase III randomized study of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with either rituximab or iodine I-131 tositumomab (monoclonal antibody anti-B1) in patients with newly diagnosed follicular non-Hodgkin’s lymphoma.
* Rituximab 375 mg/m2
